Document is current
Any future updates will be listed below
-
Authors
Monge, Cecilia https://orcid.org/0000-0002-5558-2744
Xie, Changqing https://orcid.org/0000-0002-5271-0050
Myojin, Yuta
Coffman, Kelley
Hrones, Donna Mabry
Wang, Sophie
Hernandez, Jonathan M
Wood, Bradford J
Levy, Elliot B
Juburi, Israa
Hewitt, Stephen M
Kleiner, David E https://orcid.org/0000-0003-3442-4453
Steinberg, Seth M
Figg, William D
Redd, Bernadette
Homan, Philip
Cam, Maggie
Ruf, Benjamin https://orcid.org/0000-0002-2501-4471
Duffy, Austin G
Greten, Tim F https://orcid.org/0000-0002-0806-2535
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03206073 at ClinicalTrials.govnct03860272 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
https://doi.org/10.1136/jitc-2022-005640
Documents that mention this clinical trial
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).
https://doi.org/10.1200/jco.2023.41.4_suppl.lba8
778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors
https://doi.org/10.1136/jitc-2022-sitc2022.0778
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
https://doi.org/10.1200/jco-24-02524
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
https://doi.org/10.1136/jitc-2022-005640
Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer
https://doi.org/10.1136/jitc-2025-013222
398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy
https://doi.org/10.1136/jitc-2020-sitc2020.0398
Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.
https://doi.org/10.1200/jco.2024.42.16_suppl.3556
-
Funding
Funding for this research was provided by:
Astra - Zeneca (N/A)
Sillajen (N/A)
the Intramural Research Program of the NIH, NCI (BC 011343)
- License Information
